HOTH

Newswire

[ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
[ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
[ February 5, 2025 ] Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Newsmakers
[ February 5, 2025 ] Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Newsmakers
[ January 30, 2025 ] BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG) Newsmakers
[ January 30, 2025 ] ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation Newsmakers
[ January 30, 2025 ] Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Newsmakers
[ January 30, 2025 ] Alpha Modus (NASDAQ: AMOD) Secures 9th AI Patent, Strengthening Leadership in Retail Innovation Newsmakers
[ January 29, 2025 ] NEWTON GOLF Company (NASDAQ: SPGC) Provides Preliminary Financial Results for Fourth Quarter 2024 and Full Year 2024 Newsmakers
[ January 28, 2025 ] NanoVibronix (NASDAQ: NAOV)Advances Development of PainShield and UroShield with Completion of NextGen Prototypes Newsmakers

Hoth Therapeutics (NASDQ: HOTH) to Attend Benchmark’s 8th Annual Discovery 1×1 Conference

November 18, 2019 admin Comments Off

NEW YORK, Nov. 18, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]

Hoth Therapeutics (NASDAQ: HOTH) Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication

November 14, 2019 admin Comments Off

NEW YORK, Nov. 14, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]

Hoth Therapeutics (NASDAQ: HOTH) to Present at the Dawson James 5th Annual Small Cap Growth Conference

October 15, 2019 admin Comments Off

NEW YORK, Oct. 15, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound […]

Hoth Therapeutics (NASDAQ: HOTH) Makes Donation to National Eczema Association in Sponsorship of “National Eczema Awareness Month”

October 14, 2019 admin Comments Off

NEW YORK, Oct. 14, 2019 — Hoth Therapeutics, Inc.(NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound […]

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

October 4, 2019 admin Comments Off

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock investor conference presentation 9/26/2019 Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, […]

Hoth Therapeutics (NASDAQ: HOTH) to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

September 6, 2019 admin Comments Off

NEW YORK, Sept. 6, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, […]

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Issues Letter to Shareholders

September 4, 2019 admin Comments Off

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today issued a letter to shareholders. Dear Shareholder, I […]

Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

August 29, 2019 admin Comments Off

Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]